Celsion Co. (NASDAQ:CLSN) Director Alberto R. Martinez, Jr. acquired 7,143 shares of Celsion stock in a transaction on Thursday, February 22nd. The shares were bought at an average cost of $2.17 per share, with a total value of $15,500.31. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at $43,400. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Celsion Co. (NASDAQ CLSN) traded up $0.01 during mid-day trading on Thursday, reaching $2.14. 227,900 shares of the company’s stock were exchanged, compared to its average volume of 396,302. The company has a market capitalization of $34.53, a PE ratio of -0.36 and a beta of 1.81. Celsion Co. has a 1 year low of $1.24 and a 1 year high of $6.06.
A number of research firms have commented on CLSN. ValuEngine cut shares of Celsion from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research cut shares of Celsion from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Finally, Oppenheimer began coverage on shares of Celsion in a research report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $11.90.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.